Additive or sequential nucleoside analogue therapy compared with continued zidovudine monotherapy in human immunodeficiency virus-infected patients with advanced disease does not prolong survival: An observational study

Journal of Infectious Diseases

Volumn 175, Issue 6, 1997, Pages 1344-1351

  Van Leeuwen, Remko ^a   Bonsel, Gouke J ^b   Reiss, Peter ^b   Danner, Sven A ^b   Lange, Joep M A ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; DIDANOSINE; PENTAMIDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; DRUG EFFICACY; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0030946143     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516466     Document Type: Article

References (13)

1. Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993;37:1207-13.
2. Boucher CA. Clinical significance of zidovudine-resistant human immunodeficiency viruses. Res Virol 1992;143:134-6.
3. Watson AJ, Wilburn LM. Inhibition of HIV infection of resting peripheral blood lymphocytes by nucleosides. AIDS Res Hum Retroviruses 1992;8:1221-7.
4. Gao WY, Shirasaka T, Johns DG, Broder S, Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993;91:2326-33.
5. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected patients. Lancet 1996;348:283-91.
6. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
7. Meng TC, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med 1992;116:13-20 (comment in: Ann Intern Med 1992;116:85-6).
8. Fischl MA, Stanley K, Collier AC, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995;122:24-32 (comment in: Ann Intern Med 1995;123:395).
9. Yarchoan R, Lietzau JA, Nguyen BY, et al. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis 1994;169:9-17 (erratum: J Infect Dis 1994;170:260).
10. Schooley RT, Ramirez-Ronda C, Lange JM, et al. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J Infect Dis 1996;173:1354-66.
11. Larder BA, Kohli A, Bloor S, et al. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′,3′-dideoxyinosine or AZT plus 2′,3′-dideoxycytidine combination therapy. J Virol 1996;70:5922-9.
12. van Everdingen JJ, Lange JM. Consencus vroegtijdige intervenue met zidovudine. Ned Tijdschr Geneeskd 1991;135:1547-50.
13. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36(suppl S1):1S-5S.